The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration

Hepatology

Volumn 66, Issue 2, 2017, Pages 518-527

  Deneau, Mark R ^a   El Matary, Wael ^b   Valentino, Pamela L ^c   Abdou, Reham ^d   Alqoaer, Khaled ^e   Amin, Mansi ^f   Amir, Achiya Z ^g   Auth, Marcus ^h   Bazerbachi, Fateh ⁱ   Broderick, Annemarie ^j   Chan, Albert ^k   Cotter, Jillian ^l   Doan, Sylvia ^a   El Youssef, Mounif ⁱ   Ferrari, Federica ^m   Furuya, Katryn N ^i,n   Gottrand, Madeleine ^o   Gottrand, Frederic ^o   Gupta, Nitika ^p   Homan, Matjaz ^q   Kamath, Binita M ^r   Kim, Kyung Mo ^s   Kolho, Kaija Leena ^t   Konidari, Anastasia ^u   Koot, Bart ^v   Iorio, Raffaele ^w   Ledder, Oren ^x   Mack, Cara ^l   Martinez, Mercedes ^y   Miloh, Tamir ^z   Mohan, Parvathi ^aa   O'Cathain, Niamh ^j   Papadopoulou, Alexandra ^ab   Ricciuto, Amanda ^r   Saubermann, Lawrence ^k   Sathya, Pushpa ^ac   Shteyer, Eyal ^x   Smolka, Vratislav ^ad   Tanaka, Atushi ^ae   Varier, Raghu ^af   Venkat, Veena ^ag   Vitola, Bernadette ^ah   Vos, Miriam B ^p   Woynarowski, Marek ^ai   Yap, Jason ^aj   Jensen, M Kyle ^a   more..

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e King Salman Armed Force Hospital   (Saudi Arabia)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g TEL AVIV UNIVERSITY   (Israel)

^h ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY COLLEGE DUBLIN   (Ireland)

^k UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^l UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF LJUBLJANA   (Slovenia)

^r UNIVERSITY OF TORONTO   (Canada)

^s University of Ulsan   (South Korea)

^t UNIVERSITY OF HELSINKI   (Finland)

^u UNIVERSITY OF LIVERPOOL   (United Kingdom)

^v ACADEMIC MEDICAL CENTER   (Netherlands)

^w UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^x SHAARE ZEDEK MEDICAL CENTER   (Israel)

^y New York Presbyterian Columbia University Medical Center   (United States)

^z PHOENIX CHILDREN'S HOSPITAL   (United States)

^aa CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^ab UNIVERSITY OF ATHENS   (Greece)

^ac MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^ad PALACKÝ UNIVERSITY   (Czech Republic)

^ae TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^af Northwest Gastroenterology Clinic   (United States)

^ag UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^ah MEDICAL COLLEGE OF WISCONSIN   (United States)

^ai CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^aj UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALOPECIA AREATA; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; EPIDERMOLYSIS BULLOSA; FEMALE; FOLLOW UP; HISTORY; HUMAN; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SCLEROSING CHOLANGITIS; SURVIVAL; THROMBOCYTE; ANALYSIS OF VARIANCE; CHILD; CHOLANGITIS, SCLEROSING; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; INTERNATIONAL COOPERATION; JAPAN; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CHILD; CHOLANGITIS, SCLEROSING; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONALITY; JAPAN; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 85021369385     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29204     Document Type: Article

References (41)

1. Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013;58:1392-1400.
2. Valentino PL, Wiggins S, Harney S, Raza R, Lee CK, Jonas MM. The natural history of primary sclerosing cholangitis in children: a large single center longitudinal cohort study. J Pediatr Gastroenterol Nutr 2016;63:603-609.
3. Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St Louis P, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-1422.
4. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-217.
5. Batres LA, Russo P, Mathews M, Piccoli DA, Chuang E, Ruchelli E. Primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol 2005;8:568-576.
6. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009;7:239-245.
7. Yoon J, Oh SH, Kim HJ, Park SH, Ye BD, Yang SK, et al. Primary sclerosing cholangitis with inflammatory bowel disease in Korean children. Pediatr Gastroenterol Hepatol Nutr 2015;18:268-275.
8. Smolka V, Karaskova E, Tkachyk O, Aiglova K, Ehrmann J, Michalkova K, et al. Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis. Hepatobiliary Pancreat Dis Int 2016;15:412-418.
9. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
10. Mileti E, Rosenthal P, Peters MG. Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. Clin Gastroenterol Hepatol 2012;10:417-421.
11. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-1207.
12. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
13. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340-361.
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
15. Mayo Medical Laboratories. Alkaline phosphatase, total and isoenzymes, serum. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/89503.
16. Weismuller TJ, Hansen BE, Trivedi PJ, Imam M, Lenzen H, Ponsioen CY, et al. Gender and IBD phenotype are independent predictors of death or transplantation and of malignancy in primary sclerosing cholangitis—a multicenter retrospective study of the International PSC Study Group (IPSCSG) [Abstract]. Hepatology 2015;62:246A.
17. Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int 2008;28:983-989.
18. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
19. Treeprasertsuk S, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology 2010;51:1302-1310.
20. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004;39:204-210.
21. Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012;24:1051-1058.
22. Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151-156.
23. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-526.
24. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50:158-164.
25. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48:1106-1117.
26. Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646-659; quiz 660.
27. Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygard S, Godang K, et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 2015;62:188-197.
28. Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014;146:970-979; quiz e915-976.
29. Petersen JR, Stevenson HL, Kasturi KS, Naniwadekar A, Parkes J, Cross R, et al. Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol 2014;48:370-376.
30. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
31. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-694.
32. Watanabe T, Hirano K, Tada M, Isayama H, Mizuno S, Arizumi T, et al. Short-term prognostic factors for primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2015;22:486-490.
33. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013;58:329-334.
34. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011;43:309-313.
35. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002;35:1494-1500.
36. Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-980.
37. Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731-735.
38. Naess S, Bjornsson E, Anmarkrud JA, Al Mamari S, Juran BD, Lazaridis KN, et al. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int 2014;34:1488-1495.
39. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.
40. Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008;42:522-526.
41. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521-536.